A cervical cancer drug may elevate the risk of developing ocular surface disease, such as conjunctival scarring and infectious keratitis.

Pulmocide's investigational product, opelconazole, is currently in a Phase 3 clinical trial (NCT05238116) in patients with Invasive Pulmonary Aspergillosis (IPA) who are not responding to antifungal ...